Key Details
Price
$1.14Annual ROE
601.92%Beta
0.97Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 22, 2023Recent annual earnings:
Mar 22, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass. , Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. , Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
FAQ
- What is the ticker symbol for NeuroSense Therapeutics?
- Does NeuroSense Therapeutics pay dividends?
- What sector is NeuroSense Therapeutics in?
- What industry is NeuroSense Therapeutics in?
- What country is NeuroSense Therapeutics based in?
- When did NeuroSense Therapeutics go public?
- Is NeuroSense Therapeutics in the S&P 500?
- Is NeuroSense Therapeutics in the NASDAQ 100?
- Is NeuroSense Therapeutics in the Dow Jones?
- When was NeuroSense Therapeutics's last earnings report?
- When does NeuroSense Therapeutics report earnings?
- Should I buy NeuroSense Therapeutics stock now?